Hefty $6 Billion Deal: Hengrui Licenses GLP-1 Portfolio to Hercules
License out/in
Hengrui Medicine, a leading innovative global pharmaceutical company, has announced a landmark deal. The company has granted the exclusive rights to develop, manufacture, and commercialize its proprietary GLP-1 class of innovative drugs - HRS-7535, HRS9531, and HRS-4729 - to Hercules, a new biopharmaceutical company based in the United States.
Hercules, founded in May 2024, is backed by a consortium of prominent investment firms, including Bain Capital Life Sciences Fund, Atlas Ventures, RTW Capital, and Lyra Capital, who have collectively invested $400 million to establish the company. Bain Capital Life Sciences Fund, established in 2016, has a global investment focus on the pharmaceutical, biotechnology, medical device, diagnostics, and life sciences tool sectors, with a particular emphasis on driving medical innovation and addressing unmet healthcare needs.
Under the terms of the agreement, Hercules will pay Hengrui an upfront payment and near-term milestone payments totaling $110 million, as well as up to $200 million in clinical development and regulatory milestones, and up to $5.725 billion in sales milestones, along with tiered royalties on net sales ranging from low single-digit to low double-digit percentages. In exchange, Hengrui will acquire a 19.9% equity stake in Hercules.
Hengrui's innovative GLP-1 portfolio holds significant promise for the treatment of type 2 diabetes (T2DM) and obesity. HRS-7535, an oral small-molecule GLP-1 receptor agonistGLP-1 receptor agonist, can enhance insulin secretion, suppress glucagon release, and increase satiety, making it a potential game-changer in the management of T2DM and weight loss. HRS9531, a dual agonist targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the GLP-1 receptor, aims to synergistically promote insulin secretion, suppress energy intake, and improve insulin sensitivity, while mitigating the gastrointestinal side effects associated with GLP-1 agonists.
The licensing deal underscores Hengrui's commitment to advancing its innovative pipeline and making its research and development achievements accessible to patients globally. With over a decade of R&D investments totaling nearly $40 billion, Hengrui has already launched 16 innovative drugs and 4 second-class new drugs in China, with more than 90 self-developed innovative products in various stages of development.
This landmark partnership with Hercules is set to further strengthen Hengrui's position as a leading global biopharmaceutical player, as it continues to drive medical innovation and address unmet healthcare needs worldwide.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.